BIM 23014 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
67Polycystic kidney disease1

67. Polycystic kidney disease


Clinical trials : 221 Drugs : 212 - (DrugBank : 55) / Drug target genes : 40 - Drug target pathways : 151
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2011-005017-37-NL
(EUCTR)
30/05/201221/05/2012To investigate the effect of Lanreotide on renal function decline in ADPKD patientsA randomised, controlled clinical trial assessing the efficacy ofLanreotide to halt disease progression in ADPKD - The DIPAK 1 Study First, to demonstrate whether Lanreotide attenuates progression of the renal phenotype in ADPKD patients as measuredby change in rate of renal function decline and change in renal volume. Second, to demonstrate whether Lanreotidemodifies progression of the liver phenotype in the subset of ADPKD patients with moderate to severe polycystic liverdisease as measured by change in liver volume.
MedDRA version: 14.1;Level: LLT;Classification code 10023433;Term: Kidney polycystic;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Somatuline Autogel
Product Name: Lanreotide
Product Code: BIM 23014
INN or Proposed INN: Lanreotide
Other descriptive name: LANREOTIDE ACETATE
DIPAK ConsortiumNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Netherlands